Jump to main content
Jump to site search

Issue 36, 2011
Previous Article Next Article

Metal-based antitumour drugs in the post-genomic era: what comes next?

Author affiliations

Abstract

In our Dalton Transactions Perspective article entitled, ‘Metal-based antitumour drugs in the post genomic era', (Dalton Trans., 2006, 1929–1933) we discussed metal-based drugs in light of past decades of research. We concluded that the post-genomic era would dictate a change in the direction of the field with knowledge of the genome increasingly allowing protein targets to be identified and not simply assuming that DNA is the only relevant target of metal-based drugs. Since our article was published new insights into the mode of action of metal-based drugs have emerged making some older findings increasingly relevant to current drug design. In this article we discuss these developments in terms of what we believe should be the future direction for the field.

Graphical abstract: Metal-based antitumour drugs in the post-genomic era: what comes next?

Back to tab navigation

Publication details

The article was received on 28 Mar 2011, accepted on 18 May 2011 and first published on 04 Jul 2011


Article type: Perspective
DOI: 10.1039/C1DT10522A
Dalton Trans., 2011,40, 9069-9075

  •   Request permissions

    Metal-based antitumour drugs in the post-genomic era: what comes next?

    G. Sava, A. Bergamo and P. J. Dyson, Dalton Trans., 2011, 40, 9069
    DOI: 10.1039/C1DT10522A

Search articles by author

Spotlight

Advertisements